Incyte (INCY) Guggenheim Inaugural Global Healthcare Innovation Conference summary

R&D strategy and pipeline evolution

• Increased rigor in R&D decision-making, challenging assumptions with internal and external data.

• Terminated programs not meeting high standards, reallocating capital to higher-potential projects.

• Focused on three main therapeutic areas, with expansion in inflammation and immunity, including allergy and asthma.

• Recommitted to solid tumor oncology, advancing G12D and TGF-beta receptor 2 by PD-1 programs.

• Accelerating AI and machine learning integration in R&D for target discovery and drug development.

Capital allocation and business development

• Acquired Escient, adding two assets in inflammatory and autoimmune indications.

• Executed a $2 billion share repurchase due to perceived undervaluation and strong balance sheet post-acquisition.

• Pipeline now well-balanced across focus areas and stages; current priority is internal R&D investment.

• Future BD will target complementary or near-commercial assets, with opportunistic approach based on valuation.

• Capital allocation decisions will adapt as priorities evolve, balancing internal growth, BD, and capital returns.

Key pipeline updates and clinical programs

• Jakafi XR (once-daily) bioequivalence data expected early 2025, aiming for smoother transition post-LOE in 2028.

• BET inhibitor advancing to phase 3, with updated data and trial design to be disclosed later this year.

• Mutant CALR antibody and JAK2 V617F inhibitor progressing in phase 1, with data expected next year.

• Axatilimab (Niktimvo) for chronic GVHD launching in Q1, targeting $400–500 million opportunity.

• Opzelura pediatric AD approval expected in 2025, representing 10–15% of U.S. AD opportunity.